Abstract

This document provides methods and materials for treating cancer. For example, foamy viruses (e.g., simian foamy viruses) are provided as well as methods and materials for treating cancer using foamy viruses as an oncolytic agent.

IPC Classes  ?

• A61K 35/768 - Oncolytic viruses not provided for in groups
• A61P 35/00 - Antineoplastic agents
• C12N 7/00 - Viruses, e.g. bacteriophagesCompositions thereofPreparation or purification thereof

Abstract

This document provides methods and materials involved in treating cancer. For example, a level of an autoimmune regulator (AIRE) polypeptide within a mammal can be altered (e.g., increased or decreased) to expose one or more epitopes of a tumor-specific antigen within a cancer cell present in the mammal (e.g., such that the mammal produces an immune response against the cancer cell). In some cases, one or more modulators of an AIRE polypeptide level can be administered to a mammal having cancer (e.g., a cancer that exhibits little or no response to treatment with immune checkpoint inhibitors) to treat the mammal.

IPC Classes  ?

• A61K 38/17 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans
• A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
• A61K 48/00 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseasesGene therapy
• A61P 35/00 - Antineoplastic agents
• C07K 16/44 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material not provided for elsewhere
• C12Q 1/6886 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
• G01N 33/574 - ImmunoassayBiospecific binding assayMaterials therefor for cancer
• A61P 37/02 - Immunomodulators

Abstract

The invention pertains to treating kidney disease and systems and methods for determining the rate of net fluid removal to be used during CKRT. According to the invention, determining the rate of net fluid removal includes calculating a predicted body weight of the patient based on patient's height, determining a net fluid removal rate from the patient in volume/mass/time based on the predicted body weight of the patient and a restrictive or a liberal strategy, calculating a total rate of continuous intravenous fluids infused into the patient in volume/mass/time, and adding the total rate of continuous intravenous fluids infused to the net fluid removal rate. The net fluid removal rate is used to set the continuous dialysis machine to remove a corresponding fluid volume from the patient during CKRT.

IPC Classes  ?

• A61M 1/16 - Dialysis systemsArtificial kidneysBlood oxygenators with membranes
• G16H 10/60 - ICT specially adapted for the handling or processing of patient-related medical or healthcare data for patient-specific data, e.g. for electronic patient records

Abstract

Aqueous ocular topical pharmaceutical formulations are provided that deliver an effective amount of (lev)cromakalim or a pharmaceutically acceptable salt thereof to treat an anterior or a posterior ocular disorder that responds to (lev)cromakalim, including glaucoma. Aqueous ocular topical pharmaceutical formulations are provided that deliver an effective amount of (lev)cromakalim or a pharmaceutically acceptable salt thereof to treat an anterior or a posterior ocular disorder that responds to (lev)cromakalim, including glaucoma.

IPC Classes  ?

• A61K 9/00 - Medicinal preparations characterised by special physical form
• A61K 31/4025 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
• A61K 47/10 - AlcoholsPhenolsSalts thereof, e.g. glycerolPolyethylene glycols [PEG]PoloxamersPEG/POE alkyl ethers
• A61K 47/26 - Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharidesDerivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
• A61K 47/32 - Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers
• A61K 47/44 - Oils, fats or waxes according to two or more groups of Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin

Abstract

Aqueous ocular topical pharmaceutical formulations are provided that deliver an effective amount of (lev)cromakalim or a pharmaceutically acceptable salt thereof to treat an anterior or a posterior ocular disorder that responds to (lev)cromakalim, including glaucoma. Aqueous ocular topical pharmaceutical formulations are provided that deliver an effective amount of (lev)cromakalim or a pharmaceutically acceptable salt thereof to treat an anterior or a posterior ocular disorder that responds to (lev)cromakalim, including glaucoma.

IPC Classes  ?

• A61K 31/4025 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
• A61K 9/00 - Medicinal preparations characterised by special physical form
• A61K 47/10 - AlcoholsPhenolsSalts thereof, e.g. glycerolPolyethylene glycols [PEG]PoloxamersPEG/POE alkyl ethers
• A61K 47/14 - Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
• A61K 47/26 - Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharidesDerivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
• A61K 47/32 - Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers
• A61K 47/44 - Oils, fats or waxes according to two or more groups of Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
• A61P 27/06 - Antiglaucoma agents or miotics

Abstract

This document relates to methods and materials for providing stimulation or ablation to the stellate ganglion. For example, this document relates to methods and devices for providing stimulation or ablation to the stellate ganglion to modify blood pressure.

IPC Classes  ?

• A61N 1/36 - Applying electric currents by contact electrodes alternating or intermittent currents for stimulation, e.g. heart pace-makers
• A61N 1/05 - Electrodes for implantation or insertion into the body, e.g. heart electrode
• A61N 1/32 - Applying electric currents by contact electrodes alternating or intermittent currents
• A61N 1/365 - Heart stimulators controlled by a physiological parameter, e.g. by heart potential

Abstract

Devices, methods, and kits can be designed and used for tissue removal. In some examples, a tissue removal device includes a handle assembly, a rechargeable battery, a motor system with a reciprocating motor shaft electrically coupled to the rechargeable battery, and a head assembly releasably coupled to the handle assembly. The head assembly can include a blade. The blade can be configured for linear movement that is transverse to a longitudinal axis of the handle assembly and responsive to a movement of the reciprocating motor shaft.

IPC Classes  ?

• A61B 17/32 - Surgical cutting instruments
• A61B 17/22 - Implements for squeezing-off ulcers or the like on inner organs of the bodyImplements for scraping-out cavities of body organs, e.g. bonesSurgical instruments, devices or methods for invasive removal or destruction of calculus using mechanical vibrationsSurgical instruments, devices or methods for removing obstructions in blood vessels, not otherwise provided for
• A61B 18/14 - Probes or electrodes therefor
• A61M 1/00 - Suction or pumping devices for medical purposesDevices for carrying-off, for treatment of, or for carrying-over, body-liquidsDrainage systems

Abstract

Devices and methods are described for accessing an intracranial extravascular space of a patient. For example, this disclosure describes devices and methods for drainage of a subdural hematoma disposed within an intracranial extravascular space of a patient.

IPC Classes  ?

• A61B 18/14 - Probes or electrodes therefor
• A61B 17/12 - Surgical instruments, devices or methods for ligaturing or otherwise compressing tubular parts of the body, e.g. blood vessels or umbilical cord
• A61B 17/32 - Surgical cutting instruments
• A61B 18/00 - Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body
• A61B 90/00 - Instruments, implements or accessories specially adapted for surgery or diagnosis and not covered by any of the groups , e.g. for luxation treatment or for protecting wound edges
• A61M 25/00 - CathetersHollow probes
• A61M 27/00 - Drainage appliances for wounds, or the like

Abstract

The invention provides prognostic methods for evaluating the severity of NMO and NMO-associated diseases as well as methods of treating NMO and NMO-associated diseases.

IPC Classes  ?

• G01N 33/564 - ImmunoassayBiospecific binding assayMaterials therefor for pre-existing immune complex or autoimmune disease
• A61K 31/439 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
• A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
• A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca

Abstract

Multiscale brain electrodes can be used for spatiotemporal mapping, probing, and therapeutic modulation of the human brain. The applications for such functional mapping and electrical stimulation modulation span, for example, neurological and psychiatric diseases, and brain rehabilitation.

IPC Classes  ?

• A61B 5/291 - Bioelectric electrodes therefor specially adapted for particular uses for electroencephalography [EEG]
• A61B 5/00 - Measuring for diagnostic purposes Identification of persons
• A61B 5/053 - Measuring electrical impedance or conductance of a portion of the body
• A61B 5/055 - Detecting, measuring or recording for diagnosis by means of electric currents or magnetic fieldsMeasuring using microwaves or radio waves involving electronic [EMR] or nuclear [NMR] magnetic resonance, e.g. magnetic resonance imaging

Abstract

A framework for software development in regulated industries enables users from different domains to collaborate effectively and create documentation and/or objective evidence for development activities using their own language and expertise. The framework provides guidance for meeting regulatory expectations, if necessary, and can also help teams quickly identify redundant workstreams, share work across teams, and increase communication between disparate groups.

IPC Classes  ?

• G06F 8/73 - Program documentation
• G06N 20/00 - Machine learning
• G06F 8/70 - Software maintenance or management
• G06N 5/022 - Knowledge engineeringKnowledge acquisition
• G06Q 10/0635 - Risk analysis of enterprise or organisation activities
• G06Q 30/018 - Certifying business or products
• G06F 8/10 - Requirements analysisSpecification techniques

Abstract

The present disclosure provides an anti-galectin-1 monoclonal antibody and methods of its use to detect intracellular or cell surface galectin-1. The disclosure also provides methods for using the anti-galectin-1 antibody to detect β-galactoside on a cell surface.

IPC Classes  ?

• C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
• G01N 33/532 - Production of labelled immunochemicals
• G01N 33/68 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving proteins, peptides or amino acids

Abstract

In some embodiments, the present disclosure provides a compound of Formula (I): In some embodiments, the present disclosure provides a compound of Formula (I): or a pharmaceutically acceptable salt thereof, wherein X1, X2, R3-R8, and n are as disclosed herein. In some embodiments, the present disclosure provides a pharmaceutical composition comprising any of the compounds as described herein, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier. In some embodiments, the present disclosure provides a method of modulating particulate guanylyl cyclase receptor A (pGC-A) in a cell, the method comprising contacting the cell with an effective amount of any one of the compounds as described herein, or a pharmaceutically acceptable salt thereof.

IPC Classes  ?

• C07D 417/12 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group containing two hetero rings linked by a chain containing hetero atoms as chain links
• A61K 31/428 - Thiazoles condensed with carbocyclic rings
• A61K 31/439 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
• A61K 31/454 - Non-condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
• A61K 31/4545 - Non-condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
• A61K 31/4709 - Non-condensed quinolines containing further heterocyclic rings
• A61K 31/506 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
• A61K 31/5377 - 1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
• A61K 31/55 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
• C07D 277/82 - Nitrogen atoms
• C07D 417/14 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group containing three or more hetero rings

Abstract

Scoring functions for predicting response of a dMMR and/or MSI-H colorectal tumor to a PD-1 axis-directed therapy are disclosed, as well as methods and systems for evaluating tissue samples for the presence of feature metrics useful in computing such scoring functions. The scoring functions integrate one or more spatial relationships between cell types into a numerical indication of the likelihood that the tumor will respond to the PD-1 axis-directed therapy. Based on the output of the scoring function, a subject may then be selected to receive a PD-1 axis-directed therapy (if the scoring function indicates a sufficient likelihood of positive response) or an alternative therapy (if the scoring function indicates an insufficient likelihood of positive response).

IPC Classes  ?

• G01N 33/574 - ImmunoassayBiospecific binding assayMaterials therefor for cancer
• G06T 7/00 - Image analysis
• G06T 7/73 - Determining position or orientation of objects or cameras using feature-based methods
• G06V 10/25 - Determination of region of interest [ROI] or a volume of interest [VOI]
• G06V 20/69 - Microscopic objects, e.g. biological cells or cellular parts
• G06V 20/70 - Labelling scene content, e.g. deriving syntactic or semantic representations

Abstract

Methods and materials for identifying and using neuron-specific extracellular vesicles are provided herein. For example, provided herein are methods and materials for identifying neuron-specific extracellular vesicles and assessing the presence and/or amount of disease biomarkers associated with the identified extracellular vesicles.

IPC Classes  ?

• G01N 33/68 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving proteins, peptides or amino acids
• C12N 5/00 - Undifferentiated human, animal or plant cells, e.g. cell linesTissuesCultivation or maintenance thereofCulture media therefor
• C12N 5/0793 - Neurons
• G01N 33/50 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing

Abstract

Generative artificial intelligence (AI) models are used to generate synthetic images from one or more radiographic images of a subject. As one example, a radiographic image of a subject in a first view can be converted to a view-corrected radiographic image of the subject in a second view. As another example, two or more radiographic images of a subject can be used to generate a three-dimensional (3D) anatomical model, such as a 3D model of bony structures in the subject. To ensure consistency of the synthetic images with the input radiographic images, a radiographic fingerprint is generated from the input images and used to condition the generative models. The radiographic fingerprint may be an embedding vector that encodes unique anatomical features depicting in the input images.

IPC Classes  ?

• G06V 10/44 - Local feature extraction by analysis of parts of the pattern, e.g. by detecting edges, contours, loops, corners, strokes or intersectionsConnectivity analysis, e.g. of connected components
• G06T 3/02 - Affine transformations
• G06T 17/00 - 3D modelling for computer graphics
• G06V 10/774 - Generating sets of training patternsBootstrap methods, e.g. bagging or boosting

Goods & Services

Systematization of data in computer databases; Updating and maintenance of data in computer databases; Data processing services; Database management Platform as a service (PAAS) featuring computer software platforms for analysis of medical patient data; Providing online non-downloadable software programs for use in analyzing and compiling clinical health care data; Providing online non-downloadable software programs for use in analyzing and compiling data relating to medical conditions, treatments, and therapies; Scientific research in the nature of conducting clinical trials for others in the field of health care, namely relating to development of digital biomarkers or endpoints to support improved patient care; Development, updating and maintenance of software and database systems; Artificial intelligence as a service (AIAAS) services featuring software using artificial intelligence (AI) for Early Disease Detection and Predictive Insights, such as pre-screening patients for clinical trials; Providing an on-line searchable database in the field of biopharmaceuticals and pharmaceuticals for scientific research purposes; Medical research services; Pharmaceutical research services; Research and development of medicines; Pharmaceutical drug development services; Medical and scientific research, namely, conducting clinical trials for others; Providing medical and scientific research information in the field of clinical trials; Providing medical and scientific research information in the field of pharmaceuticals and clinical trials; Consulting services for others in the field of design, planning, and implementation project management of scientific research and clinical trials; Research and development services in the field of medical preparations; Scientific study and research in the field of medicine, the prevention, treatment and management of illness, health care delivery; Platform as a service (PAAS) featuring cloud computing tools for development of statistical models, data analytics, machine learning, and artificial intelligence models in the field of health care; Providing access to an online non-downloadable data network program that synthesizes and analyzes health care data; Remote monitoring of medical data for research purposes; Providing an online searchable database featuring de-identified clinical patient data; Providing an online searchable database containing information for use by data scientists in the fields of health diseases and disorders; Data compiling and analyzing health data in the field of health care; Updating and maintenance of database systems, which refers collectively to the database model, database management system and database content; Consulting services in the field of medical device development and design; Medical device development, namely, product development services for others in the field of medical devices; Biotechnology consulting; Product design and development in the field of medical devices Remote monitoring of medical data for medical diagnosis and treatment; Remote monitoring of data indicative of the health or condition of an individual or group of individuals for medical diagnosis and treatment purposes; Health care services, namely, providing a database in the field of Early Disease Detection information and featuring inputting and collection of data and information all for treatment and diagnostic purposes; Medical diagnostic services; Providing an internet website for medical professionals and medical patients featuring medical information from remote locations via electronic patient monitoring devices that feed information to the web site that can be accessed in real-time by medical professionals for purposes of monitoring and diagnosing medical conditions; Medical testing for diagnostic or treatment purposes; Medical diagnostic, testing, monitoring and reporting services; Providing an internet website for medical professionals and medical patients featuring medical information from remote locations via devices that feed information to the website that is processed, exchanged and accessed in real-time by users; Providing on-line medical record analysis services designed to provide patients with custom tailored information about the range of possible diagnoses and therapies associated with a defined set of symptoms

Goods & Services

Systematization of data in computer databases; Updating and maintenance of data in computer databases; Data processing services; Database management Platform as a service (PAAS) featuring computer software platforms for analysis of medical patient data; Providing online non-downloadable software programs for use in analyzing and compiling clinical health care data; Providing online non-downloadable software programs for use in analyzing and compiling data relating to medical conditions, treatments, and therapies; Scientific research in the nature of conducting clinical trials for others in the field of health care, namely relating to development of digital biomarkers or endpoints to support improved patient care; Development, updating and maintenance of software and database systems; Artificial intelligence as a service (AIAAS) services featuring software using artificial intelligence (AI) for Early Disease Detection and Predictive Insights, such as pre-screening patients for clinical trials; Providing an on-line searchable database in the field of biopharmaceuticals and pharmaceuticals for scientific research purposes; Medical research services; Pharmaceutical research services; Research and development of medicines; Pharmaceutical drug development services; Medical and scientific research, namely, conducting clinical trials for others; Providing medical and scientific research information in the field of clinical trials; Providing medical and scientific research information in the field of pharmaceuticals and clinical trials; Consulting services for others in the field of design, planning, and implementation project management of scientific research and clinical trials; Research and development services in the field of medical preparations; Scientific study and research in the field of medicine, the prevention, treatment and management of illness, health care delivery; Platform as a service (PAAS) featuring cloud computing tools for development of statistical models, data analytics, machine learning, and artificial intelligence models in the field of health care; Providing access to an online non-downloadable data network program that synthesizes and analyzes health care data; Remote monitoring of medical data for research purposes; Providing an online searchable database featuring de-identified clinical patient data; Providing an online searchable database containing information for use by data scientists in the fields of health diseases and disorders; Data compiling and analyzing health data in the field of health care; Updating and maintenance of database systems, which refers collectively to the database model, database management system and database content; Consulting services in the field of medical device development and design; Medical device development, namely, product development services for others in the field of medical devices; Biotechnology consulting; Product design and development in the field of medical devices Remote monitoring of medical data for medical diagnosis and treatment; Remote monitoring of data indicative of the health or condition of an individual or group of individuals for medical diagnosis and treatment purposes; Health care services, namely, providing a database in the field of Early Disease Detection information and featuring inputting and collection of data and information all for treatment and diagnostic purposes; Medical diagnostic services; Providing an internet website for medical professionals and medical patients featuring medical information from remote locations via electronic patient monitoring devices that feed information to the web site that can be accessed in real-time by medical professionals for purposes of monitoring and diagnosing medical conditions; Medical testing for diagnostic or treatment purposes; Medical diagnostic, testing, monitoring and reporting services; Providing an internet website for medical professionals and medical patients featuring medical information from remote locations via devices that feed information to the website that is processed, exchanged and accessed in real-time by users; Providing on-line medical record analysis services designed to provide patients with custom tailored information about the range of possible diagnoses and therapies associated with a defined set of symptoms

Abstract

A surgical clip with one or more premagnetized elements is configured to be delivered with an endoscope or similar device, and a system and method for manipulating tissue during a surgical procedure using such a surgical clip, are provided. At least one magnetic field source arranged external to an animal body is moved using at least one robotic actuator, and a magnetic field generated thereby is used to alter position of one or more surgical clips affixed to tissue. A surgical clip includes a tubular body structure, a grasping element, and internal elements within the body structure, wherein at least portions of one or more of the body structure and the internal elements comprise a premagnetized material configured to cooperate with a magnetic end effector external to the animal body to permit manipulation of tissue.

IPC Classes  ?

• A61B 17/10 - Surgical instruments, devices or methods for closing wounds or holding wounds closedAccessories for use therewith for applying or removing wound clampsWound clamp magazines
• A61B 17/08 - Wound clamps
• A61B 34/00 - Computer-aided surgeryManipulators or robots specially adapted for use in surgery
• A61B 17/22 - Implements for squeezing-off ulcers or the like on inner organs of the bodyImplements for scraping-out cavities of body organs, e.g. bonesSurgical instruments, devices or methods for invasive removal or destruction of calculus using mechanical vibrationsSurgical instruments, devices or methods for removing obstructions in blood vessels, not otherwise provided for

Abstract

A surgical clip with a tethered magnetic element configured to be delivered with an endoscope or similar device, and a system and method for manipulating tissue during a surgical procedure using such a surgical clip, are provided. At least one magnetic field source arranged external to an animal body is moved using at least one robotic actuator, and a magnetic field generated thereby is used to alter position of one or more surgical clips affixed to tissue. A surgical clip includes a tubular body structure, a grasping element, and internal elements within the body structure. While the surgical clip grasps tissue, the tethered magnetic element is configured to cooperate with a magnetic end effector external to the animal body for manipulation of tissue.

IPC Classes  ?

• A61B 17/10 - Surgical instruments, devices or methods for closing wounds or holding wounds closedAccessories for use therewith for applying or removing wound clampsWound clamp magazines
• A61B 17/08 - Wound clamps
• A61B 34/00 - Computer-aided surgeryManipulators or robots specially adapted for use in surgery
• A61B 17/22 - Implements for squeezing-off ulcers or the like on inner organs of the bodyImplements for scraping-out cavities of body organs, e.g. bonesSurgical instruments, devices or methods for invasive removal or destruction of calculus using mechanical vibrationsSurgical instruments, devices or methods for removing obstructions in blood vessels, not otherwise provided for

Abstract

Intramedullary nails can be used for the treatment of a bone fracture. In some embodiments, such intramedullary nails can include an elongate shaft having a longitudinal axis, a distal nail component, and a proximal nail component. In some embodiments, the intramedullary nails include a first rotatable shaft and a second rotatable shaft. In some embodiments, the intramedullary nails include a handle coupled to the first and second rotatable shafts.

IPC Classes  ?

• A61B 17/72 - Intramedullary devices, e.g. pins or nails
• A61B 17/68 - Internal fixation devices
• A61B 17/88 - Methods or means for implanting or extracting internal fixation devices
• A61B 17/90 - Guides therefor

Abstract

This disclosure provides compounds of Formula (I), and pharmaceutically acceptable salts thereof that are useful for treating a disease associated with TGR5.

IPC Classes  ?

• C07D 235/18 - BenzimidazolesHydrogenated benzimidazoles with aryl radicals directly attached in position 2
• A61K 31/4184 - 1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
• A61K 31/423 - Oxazoles condensed with carbocyclic rings
• A61K 31/428 - Thiazoles condensed with carbocyclic rings
• A61K 31/437 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
• A61P 35/00 - Antineoplastic agents
• C07D 263/57 - Aryl or substituted aryl radicals
• C07D 277/66 - Benzothiazoles with only hydrocarbon or substituted hydrocarbon radicals attached in position 2 with aromatic rings or ring systems directly attached in position 2
• C07D 471/04 - Ortho-condensed systems
• C07D 498/04 - Ortho-condensed systems
• C07D 513/04 - Ortho-condensed systems

Abstract

111 is a positron emitter.

IPC Classes  ?

• C07B 59/00 - Introduction of isotopes of elements into organic compounds
• C07C 331/28 - Isothiocyanates having isothiocyanate groups bound to carbon atoms of six-membered aromatic rings
• C07K 7/06 - Linear peptides containing only normal peptide links having 5 to 11 amino acids
• G01N 23/00 - Investigating or analysing materials by the use of wave or particle radiation, e.g. X-rays or neutrons, not covered by groups , or

Abstract

This document relates to methods and materials involved in treating a mammal (e.g., a human) having cancer and/or an infectious disease. For example, this document provides recombinant human cytomegalovirus (hCMV) vectors that include (e.g., are designed to include) nucleic acid encoding a viral gene transfer vector genome (e.g., a heterologous viral gene transfer vector genome) and one or more nucleic acids encoding a packaging polypeptide such that a cell of a mammal that is infected with the hCMV vector can produce and release the viral vector (e.g., an infectious lentiviral vector) which can then infect cells (e.g., immune cells) in vivo and can, optionally, drive expression of an exogenous polypeptide (e.g., a therapeutic polypeptide or an antigen receptor such as a chimeric antigen receptor (CAR)) in the infected immune cells within a mammal (e.g., a human) to induce an immune response within the mammal are provided.

IPC Classes  ?

• A61K 35/17 - LymphocytesB-cellsT-cellsNatural killer cellsInterferon-activated or cytokine-activated lymphocytes
• A61K 39/00 - Medicinal preparations containing antigens or antibodies
• C07K 14/005 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from viruses
• C07K 14/725 - T-cell receptors
• C12N 15/86 - Viral vectors

Abstract

Systems and methods for measuring material properties of a medium are described. Operations include receiving data from a receiver such as an ultrasound receiver, the data including a representation of particle motion over time in a spatial dimension, generating a time delay map from the data, wherein a first axis of the time delay map corresponds to each of a plurality of points in the spatial dimension as a measurement point and wherein a second axis of the time delay map corresponds to each of the plurality of points in the first spatial dimension as a reference point; determining a time delay surface based on a maximum value of a cross-correlation function for the time delay map, wherein the cross-correlation function is configured to determine a relationship between a plurality of measurement points and a plurality of reference points, and determining a wave velocity based on the time delay surface.

IPC Classes  ?

• A61B 8/08 - Clinical applications
• A61B 5/02 - Detecting, measuring or recording for evaluating the cardiovascular system, e.g. pulse, heart rate, blood pressure or blood flow

Abstract

This document provides devices and methods for prosthetic flap valve system, comprising an elongation member having a first end and a second end, a first anchor member coupled to the first end of the elongation member and configured to couple the first end of the elongation member to the gastric wall of a subject, a second anchor member coupled to the second end of the elongation member and configured to couple the second end of the elongation member to a flap valve, wherein, the elongation member is configured to bias the flap valve to a closed position, and the closed position of the flap valve provides a separation between the esophagus and the stomach.

IPC Classes  ?

• A61B 17/122 - Clamps or clips, e.g. for the umbilical cord
• A61B 17/128 - Surgical instruments, devices or methods for ligaturing or otherwise compressing tubular parts of the body, e.g. blood vessels or umbilical cord for applying or removing clamps or clips
• A61F 2/04 - Hollow or tubular parts of organs, e.g. bladders, tracheae, bronchi or bile ducts
• A61F 5/00 - Orthopaedic methods or devices for non-surgical treatment of bones or jointsNursing devices
• A61B 17/04 - Surgical instruments, devices or methods for closing wounds or holding wounds closedAccessories for use therewith for suturing woundsHolders or packages for needles or suture materials

Abstract

X-ray detector efficiency and/or resolution are improved by using x-ray fluorescent materials in the x-ray detector design. The x-ray fluorescent components capture incident x-rays and emit fluorescent x-rays that are detected by adjacent x-ray detector elements. A component of the x-ray detector may be made x-ray fluorescent by incorporating a high-Z element-containing material into the x-ray detector component design. The x-ray fluorescent detector component may be an interpixel reflecting septa, a backing layer, and/or an interdetector reflector for multilayer detectors.

IPC Classes  ?

• G01T 1/20 - Measuring radiation intensity with scintillation detectors

Abstract

Devices, systems, and methods described in this disclosure can be used to deliver electroporation and adjunct therapies to treat anastomotic leaks and the resulting abscess cavities around the GI tract, within the thoracic cavity, and elsewhere within the human body. The thermal or non-thermal electroporation therapy can be delivered using the devices, systems, and methods described herein. In some embodiments, the electroporation energy is delivered to achieve sterilization and promote healing of spaces such as abscess cavities.

IPC Classes  ?

• A61N 1/32 - Applying electric currents by contact electrodes alternating or intermittent currents

Abstract

Provided are antibodies specific for the long isoform of QSOX1 and methods of using these antibodies to detect and measure the levels of the presence of the long and short isoforms of QSOX1 in a sample.

IPC Classes  ?

• C07K 16/40 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against enzymes
• G01N 33/573 - ImmunoassayBiospecific binding assayMaterials therefor for enzymes or isoenzymes
• A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
• A61P 35/00 - Antineoplastic agents

Abstract

Compact whole slide image (WSI) representations can be learned using a suitably trained generative model. The generative model is trained on training data using an instance-based training. Using gradient sparsity and quantization losses, the generative model learns to generate compact (e.g., sparse and binary) representations and/or embeddings of whole slide images.

IPC Classes  ?

• G06V 20/69 - Microscopic objects, e.g. biological cells or cellular parts
• G06T 7/00 - Image analysis
• G16H 50/20 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for computer-aided diagnosis, e.g. based on medical expert systems

Abstract

Provided herein are methods, systems, and computer program products for the detection and evaluation of cardiac condition in a lead-invariant manner.

IPC Classes  ?

• G16H 50/70 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for mining of medical data, e.g. analysing previous cases of other patients
• A61B 5/349 - Detecting specific parameters of the electrocardiograph cycle
• G06N 3/048 - Activation functions

Abstract

The present disclosure provides in one embodiment compounds of formula (I) that are DNA topoisomerase inhibitors useful in treating and/or preventing cardiotoxicity and cardiomyopathy in patients undergoing cardiotoxic chemotherapy, for example, with anthracycline drugs such as doxorubicin.

IPC Classes  ?

• A61K 31/395 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
• C07D 277/60 - Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
• C07D 261/20 - Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings condensed with carbocyclic rings or ring systems
• A61K 31/33 - Heterocyclic compounds

Abstract

A system for bypassing a portion of a small intestine. The system includes an occlusion device and a bypass device. The occlusion device includes a tubular body, an occlusion member at a distal end portion of the tubular body, and an anchor member at a proximal end portion of the tubular body. The bypass device includes a liner, and an anchor member at a proximal end portion of the liner.

IPC Classes  ?

• A61F 5/00 - Orthopaedic methods or devices for non-surgical treatment of bones or jointsNursing devices

Abstract

Described are platforms, systems, media, and methods for evaluating, monitoring, and/or treating a subject for brain injury based on machine learning analysis of one or more of brain imaging features, clinical features, demographic features, or speech features.

IPC Classes  ?

• A61B 5/00 - Measuring for diagnostic purposes Identification of persons
• G06N 20/00 - Machine learning

Abstract

A wearable device combines its existing functions (e.g., a headphone) with non-invasive autonomic modulation using tragus or other external auditory meatus stimulation. The wearable device can output audio to a user, such as music, podcast, etc., and further provide modulation of the vagus nerve via tragus stimulation or other external auditory meatus stimulation to treat various diseases.

IPC Classes  ?

• A61N 1/36 - Applying electric currents by contact electrodes alternating or intermittent currents for stimulation, e.g. heart pace-makers
• A61N 1/04 - Electrodes
• G16H 40/67 - ICT specially adapted for the management or administration of healthcare resources or facilitiesICT specially adapted for the management or operation of medical equipment or devices for the operation of medical equipment or devices for remote operation

Abstract

This document provides to methods and materials involved in assessing and/or treating a mammal (e.g., a human) having cancer (e.g., mesothelioma). For example, methods and materials provided herein can be used to identify a cancer (e.g., a mesothelioma) as being likely to respond to one or more immune checkpoint inhibitors. For example, methods and materials provided herein can be used to treat a mammal (e.g., a human) having cancer (e.g., mesothelioma) where the cancer treatment is selected based on whether or not the cancer is likely to be responsive to one or more immune checkpoint inhibitors.

IPC Classes  ?

• C12Q 1/6886 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
• G16B 25/10 - Gene or protein expression profilingExpression-ratio estimation or normalisation
• A61P 35/00 - Antineoplastic agents
• C12N 15/113 - Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides

Abstract

A wrap for collecting a plurality of lines, cords, tubes, or wires has been provided. In some implementations, the wrap may include a first surface and a second surface on opposite sides of the first layer, such that one may be viewed as being on the top of the first layer and the other on the bottom of the first layer when the wrap is in an unwrapped state. The first connection mechanism is removably attachable to the second connection mechanism to transition the wrap between the unwrapped state and a wrapped state. The first layer is configured to wrap around a plurality of lines, cords, tubes, or wires when the wrap is in a wrapped state, and a portion of the first layer overlaps another portion of the first layer when the wrap is in a wrapped state.

IPC Classes  ?

• A61M 25/02 - Holding devices, e.g. on the body

Abstract

This document provides methods and materials for assessing and/or treating mammals (e.g., humans) having a metabolic disorder (e.g., a congenital disorder of glycosylation (CDG)). For example, a circulating glycopeptide signature present in blood of a mammal (e.g., a human) having a CDG can be used to identify the mammal as having a phosphomannomutase 2 (PMM2)-CDG. This document also provides methods and materials for treating a mammal having a CDG (e.g., PMM2-CDG).

IPC Classes  ?

• A61K 31/7072 - Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
• A61K 31/00 - Medicinal preparations containing organic active ingredients
• A61K 31/70 - CarbohydratesSugarsDerivatives thereof

Abstract

This document relates to methods and materials for assessing and/or treating mammals (e.g., humans) having melanoma (e.g., primary cutaneous melanoma (PCM)). For example, methods and materials that can be used to determine whether or not a melanoma is likely to relapse (e.g., likely to relapse following treatment) are provided. For example, methods and materials for treating a mammal (e.g., a human) having melanoma where the treatment is selected based, at least in part, on whether or not the melanoma is likely to relapse are provided.

IPC Classes  ?

• C12Q 1/6886 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
• G01N 33/50 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing
• G01N 33/574 - ImmunoassayBiospecific binding assayMaterials therefor for cancer

Abstract

This document provides methods and materials for making recombinant viruses. For example, recombination systems including (1) a viral vector (e.g., an adenoviral vector) having a genome comprising a nucleic acid sequence (e.g., an engineered DNA sequence) including a first recombinase site of a first recombinase (e.g., a FRT site), a packaging sequence, a recombinase site of a second recombinase (e.g., a loxP site), a second recombinase site of said first recombinase (e.g., a second FRT site), and a recombinase site of a third recombinase (e.g., an attP site); and (2) a donor nucleic acid including a first recombinase site of the second recombinase (e.g., a first loxP site), a multicloning site and/or nucleic acid that can encode a polypeptide of interest, a recombinase site of the third recombinase (e.g., an attB site), and a second recombinase site of the second recombinase (e.g., a second loxP site) are provided.

IPC Classes  ?

• C12N 15/86 - Viral vectors
• A61K 48/00 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseasesGene therapy
• C12N 7/00 - Viruses, e.g. bacteriophagesCompositions thereofPreparation or purification thereof

Abstract

Systems and methods are provided for lesion depth determination in molecular breast imaging. The depth of a lesion in a breast of a subject may be determined during a molecular breast imaging (“MBI”) procedure where the resolving power of the detectors, such as gamma cameras, that degrades with distance from the face of the detector is exploited. By comparing the apparent size of a lesion in two opposing detectors, it is possible to estimate the distance of the lesion from each detector by modeling or measuring the resolution that changes with distance from the detectors. The systems and methods may be used during biopsy procedures to indicate the appropriate needle depth for biopsy of the lesion.

IPC Classes  ?

• A61B 6/50 - Apparatus or devices for radiation diagnosisApparatus or devices for radiation diagnosis combined with radiation therapy equipment specially adapted for specific body partsApparatus or devices for radiation diagnosisApparatus or devices for radiation diagnosis combined with radiation therapy equipment specially adapted for specific clinical applications
• A61B 6/12 - Arrangements for detecting or locating foreign bodies
• A61B 6/42 - Arrangements for detecting radiation specially adapted for radiation diagnosis

Abstract

A neuromodulation device is provided that comprises a flexible layer comprising a non-conductive material, in which the layer is positioned in at least a partially tubular shape. The neuromodulation device comprises at least one cathodic band comprising at least one conductive cathodic contact housed by the layer. The neuromodulation device comprises an anodic band comprising at least one anodic contact housed by the layer. The neuromodulation device comprises is configured to receive a wireless signal to power and activate the at least one cathodic contact and the at least one anodic contact in a coordinated reset cycle.

IPC Classes  ?

• A61N 1/36 - Applying electric currents by contact electrodes alternating or intermittent currents for stimulation, e.g. heart pace-makers
• A61N 1/02 - ElectrotherapyCircuits therefor Details
• A61N 1/05 - Electrodes for implantation or insertion into the body, e.g. heart electrode
• A61N 1/378 - Electrical supply

Abstract

Methods and materials are provided herein that can be used to separate healthy organs and/or tissues from organs and/or tissues to be subjected to, for example, heat or cold (e.g., during ablation procedures). Methods and materials also are provided herein that can be used to embolize blood vessels.

IPC Classes  ?

• A61L 24/00 - Surgical adhesives or cementsAdhesives for colostomy devices
• A61L 24/10 - PolypeptidesProteins

Abstract

This document provides devices, methods, and processes for an implantable urine flow sensor including a first end coupled to a first portion of a uretic stent, and a second end coupled to a second portion of the uretic stent. The implantable urine flow sensor is sized to fit within, and be operable within, an individual ureter.

IPC Classes  ?

• A61B 5/03 - Measuring fluid pressure within the body other than blood pressure, e.g. cerebral pressure

Abstract

Knowledge-based quality assurance (QA) of organ-at-risk contours in radiotherapy planning assists with contour review based on features obtained from the contours. These contour-based features are input to one or more computational models to predict, determine, or otherwise identify erroneous contours in the radiotherapy plan. The computational models may include statistical models, distance metric-based models, and/or machine learning models.

IPC Classes  ?

• G06T 7/00 - Image analysis
• G06V 10/75 - Organisation of the matching processes, e.g. simultaneous or sequential comparisons of image or video featuresCoarse-fine approaches, e.g. multi-scale approachesImage or video pattern matchingProximity measures in feature spaces using context analysisSelection of dictionaries
• G06F 18/2433 - Single-class perspective, e.g. one-against-all classificationNovelty detectionOutlier detection
• G06T 7/10 - SegmentationEdge detection
• G06V 10/74 - Image or video pattern matchingProximity measures in feature spaces

Abstract

Provided herein are methods of differentiating cell types in a cell population. The methods include removing at least some non-Chimeric Antigen Receptor (CAR)-T cells from a fluidic sample obtained from a subject without centrifuging the fluidic sample to produce a purified fluidic sample. The fluidic sample comprises CAR-T cells and the non-CAR-T cells. The methods also include capturing cells in the purified fluidic sample on a surface that comprises binding moieties that bind at least to the CAR-T cells to produce a captured cell population. In addition, the methods also include distinguishing the CAR-T cells from the non-CAR-T cells in the captured cell population using a trained machine learning model to produce a captured CAR-T cell population data set. Additional methods as well as related devices and systems are also provided.

IPC Classes  ?

• G01N 33/569 - ImmunoassayBiospecific binding assayMaterials therefor for microorganisms, e.g. protozoa, bacteria, viruses
• B01L 3/00 - Containers or dishes for laboratory use, e.g. laboratory glasswareDroppers
• C12N 5/00 - Undifferentiated human, animal or plant cells, e.g. cell linesTissuesCultivation or maintenance thereofCulture media therefor
• G01N 33/543 - ImmunoassayBiospecific binding assayMaterials therefor with an insoluble carrier for immobilising immunochemicals
• G01N 33/68 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving proteins, peptides or amino acids
• G06V 10/70 - Arrangements for image or video recognition or understanding using pattern recognition or machine learning

Abstract

Described here are systems and methods for a robust magnetic resonance elastography (“MRE”) imaging platform for rapid dynamic 3D MRE imaging. The imaging platform includes an MRE pulse sequence and advanced image reconstruction framework that work synergistically in order to greatly expand the domains where MRE can be deployed successfully.

IPC Classes  ?

• G01R 33/563 - Image enhancement or correction, e.g. subtraction or averaging techniques of moving material, e.g. flow-contrast angiography
• A61B 5/00 - Measuring for diagnostic purposes Identification of persons
• A61B 5/055 - Detecting, measuring or recording for diagnosis by means of electric currents or magnetic fieldsMeasuring using microwaves or radio waves involving electronic [EMR] or nuclear [NMR] magnetic resonance, e.g. magnetic resonance imaging
• G01R 33/48 - NMR imaging systems
• G06T 11/00 - 2D [Two Dimensional] image generation

Abstract

Disclosed herein are systems, devices, and methods for accessing a subdural space. In some embodiments, an apparatus may comprise a shaft configured to be slidably disposed within a lumen of a catheter. The shaft may be configured to be advanced distally from a distal end of the catheter and into a blood vessel of a subject. The shaft may include a perforating tip including an energy element configured to generate radiofrequency energy to form an opening through a wall of the blood vessel and dura of the subject and into an extravascular space of the subject. A curved section may be configured to be radially constrained within the lumen of the catheter and to curve toward the wall of the blood vessel and the dura upon exiting the lumen of the catheter such that the energy element is positioned to form the opening.

IPC Classes  ?

• A61M 1/00 - Suction or pumping devices for medical purposesDevices for carrying-off, for treatment of, or for carrying-over, body-liquidsDrainage systems
• A61B 18/00 - Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body
• A61B 18/14 - Probes or electrodes therefor

Abstract

A method for acquiring x-ray data from a subject and generating a computed tomography (CT) image of the subject includes receiving a set of illumination field data including an illumination field produced by each of a plurality of focal spot positions of an x-ray source, selecting at least one sequence of at least two illumination fields based on at least one subject-specific parameter, assigning an illumination field from the selected at least one sequence to each gantry rotation angle in a plurality of gantry rotation angles, acquiring x-ray data from a subject for each gantry rotation angle using a focal spot position associated with the illumination field that is assigned to the gantry rotation angle, and generating an image slice based on the acquired x-ray data for each of the plurality of gantry rotation angles. The x-ray data can include a number of photons received by the detector array.

IPC Classes  ?

• A61B 6/03 - Computed tomography [CT]
• A61B 6/00 - Apparatus or devices for radiation diagnosisApparatus or devices for radiation diagnosis combined with radiation therapy equipment
• G21K 1/02 - Arrangements for handling particles or ionising radiation, e.g. focusing or moderating using diaphragms, collimators

Abstract

Some embodiments provide a soft tissue device, such as a transverse carpal ligament cutting device having one or more balloons that are deflated when the device is in an inactive position and are inflated when the device is in an active position. Other embodiments provide a soft tissue cutting method, such as a method of cutting a transverse carpal ligament that uses a soft tissue cutting device.

IPC Classes  ?

• A61B 17/32 - Surgical cutting instruments
• A61B 17/22 - Implements for squeezing-off ulcers or the like on inner organs of the bodyImplements for scraping-out cavities of body organs, e.g. bonesSurgical instruments, devices or methods for invasive removal or destruction of calculus using mechanical vibrationsSurgical instruments, devices or methods for removing obstructions in blood vessels, not otherwise provided for
• A61B 17/30 - Surgical pincettes, i.e. surgical tweezers
• A61B 90/00 - Instruments, implements or accessories specially adapted for surgery or diagnosis and not covered by any of the groups , e.g. for luxation treatment or for protecting wound edges
• A61M 25/10 - Balloon catheters

Abstract

The invention provides a tissue cutting device comprising a handle, a first blade. and a second blade. The second blade is coupled to the handle. The second blade is rotatable relative to the first blade such that the second blade is configured to rotate between a first position and a second position. The second blade is in a same plane as the first blade when the second blade is in the first position. The second blade is rotated into a different plane from the first blade when the second blade is rotated from the first position toward the second position.

IPC Classes  ?

• A61B 17/32 - Surgical cutting instruments

Abstract

Provided herein is technology for neoplasia screening, and particularly, but not exclusively, to methods, compositions, and related uses for detecting the presence of cancer, in particular, colorectal cancer.

IPC Classes  ?

• C12Q 1/6883 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
• C12Q 1/6809 - Methods for determination or identification of nucleic acids involving differential detection
• C12Q 1/6827 - Hybridisation assays for detection of mutation or polymorphism
• C12Q 1/6853 - Nucleic acid amplification reactions using modified primers or templates
• C12Q 1/6886 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
• G01N 33/533 - Production of labelled immunochemicals with fluorescent label
• G01N 33/574 - ImmunoassayBiospecific binding assayMaterials therefor for cancer
• G16Z 99/00 - Subject matter not provided for in other main groups of this subclass

Abstract

In some embodiments, the present disclosure provides a compound(S) or (R)-N-(4.6-difluorobenzo[d]thiazol-2-yl)-1-(2-(dimethylamino)ethyl) piperidine-3-carboxamide, as described herein, or a pharmaceutically acceptable salt thereof. Pharmaceutical compositions comprising the compound, and methods of treating. e.g., metabolic diseases using the compound are also provided.

IPC Classes  ?

• C07D 417/12 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group containing two hetero rings linked by a chain containing hetero atoms as chain links
• A61K 31/454 - Non-condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
• A61P 9/12 - Antihypertensives

Abstract

Provided herein are genetically modified ungulate cells expressing a chimeric antigen receptor. Also provided herein are transgenic ungulate cells that can be used as cell carriers for the delivery of oncolytic viruses in cancer therapy. Also provided are transgenic ungulates comprising these cells, methods of making these cells, and methods of treating cancer by administering these cells to a subject in need thereof. Also provided are transgenic ungulate cells that express a chimeric antigen receptor and uses thereof.

IPC Classes  ?

• A61K 35/17 - LymphocytesB-cellsT-cellsNatural killer cellsInterferon-activated or cytokine-activated lymphocytes
• A61K 35/766 - Rhabdovirus, e.g. vesicular stomatitis virus
• A61K 39/00 - Medicinal preparations containing antigens or antibodies
• A61P 35/00 - Antineoplastic agents
• C07K 14/725 - T-cell receptors
• C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
• C12N 5/0783 - T cellsNK cellsProgenitors of T or NK cells
• C12N 15/86 - Viral vectors

Abstract

Disclosed are compounds of formula (1), formula (2), formula (75), formula (80) and formula (90): wherein R1, R2, R3, R4, and R5 can be selected from the group consisting of hydrogen, unsubstituted alkyl, substituted alkyl, unsubstituted haloalkyl, substituted haloalkyl, unsubstituted hydroxyalkyl, substituted hydroxyalkyl, benzyl, phenyl, substituted phenyl, unsubstituted alkenyl, substituted alkenyl, unsubstituted cycloalkyl, substituted cycloalkyl, hydroxy, unsubstituted alkoxy, substituted alkoxy, unsubstituted haloalkoxy, substituted haloalkoxy, unsubstituted phenoxy, substituted phenoxy, unsubstituted sulfonyloxy, substituted sulfonyloxy, carbonyl, carboxy, unsubstituted amino, substituted amino, unsubstituted amido, and substituted amido, and wherein at least one atom in R1 is replaced with a positron emitter. Also disclosed are methods for in vivo imaging of a subject using the compound of formula (1) or formula (2) or formula (75) or formula (80) or formula (90).

IPC Classes  ?

• A61K 51/04 - Organic compounds
• C07B 59/00 - Introduction of isotopes of elements into organic compounds

Abstract

A method for treating exposure of surgical mesh in a subject generally includes administering PEP to tissue adjacent to an area of exposed surgical mesh in an amount effective to treat the area of exposed surgical mesh. In another aspect, a method for treating exposure of surgical mesh in a subject generally includes surgically closing an area of exposed surgical mesh and administering PEP to epithelium adjacent to the surgical closure in an amount effective to treat the area of exposed surgical mesh. In one or more embodiments of either aspect, the amount effective to treat the area of exposed surgical mesh can be an amount effective to increase proliferation of epithelium to decrease the area of exposed surgical mesh, increase thickness of epithelium covering the surgical mesh, or increase vascularization of epithelium covering the surgical mesh.

IPC Classes  ?

• A61K 35/19 - PlateletsMegacaryocytes
• A61K 38/39 - Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin [CIG]
• A61P 41/00 - Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution

Abstract

The disclosure provides a method of using blood or fractions thereof, e.g., serum, obtained from a mammal subjected to liver surgery, for example, obtained following a partial hepatectomy, to increase the engraftment, proliferation and/or functionality of cells on a biocompatible scaffold.

IPC Classes  ?

• A61L 27/36 - Materials for prostheses or for coating prostheses containing ingredients of undetermined constitution or reaction products thereof
• A61L 27/24 - Collagen
• A61L 27/38 - Animal cells
• C12N 5/071 - Vertebrate cells or tissues, e.g. human cells or tissues

Abstract

This invention relates to methods and materials for nucleic acid delivery, vaccination, and/or treating cancer. More specifically, methods and materials for nucleic acid delivery, vaccination, and/or treating cancer using one or more recombinant adenoviruses (Ads) as an oncolytic agent are provided.

IPC Classes  ?

• C12N 7/00 - Viruses, e.g. bacteriophagesCompositions thereofPreparation or purification thereof
• A61K 35/761 - Adenovirus
• A61K 39/00 - Medicinal preparations containing antigens or antibodies

Abstract

This document provides methods and materials involved in assessing immune system profiles. For example, methods and materials for performing flow cytometry to determine the number of CD4+ lymphocytes, CD8+ lymphocytes, regulatory T cells, B cells, NK cells, granulocytes, CD14+HLA-DRlo/neg monocytes, and/or CD86+ monocytes per unit volume (e.g., cells per μL or mL) of whole blood (e.g., fresh, un-manipulated whole blood) obtained from a mammal (e.g., a human) are provided.

IPC Classes  ?

• G01N 33/569 - ImmunoassayBiospecific binding assayMaterials therefor for microorganisms, e.g. protozoa, bacteria, viruses
• A61K 38/20 - Interleukins

Abstract

This document relates to methods and materials for treating myeloid disorders in a mammal (e.g., a human). For example, methods and materials for using one or more inhibitors of early lymphopoiesis to treat a mammal having a myeloid disorder (e.g., a SF3B1-associated myeloid disorder) are provided.

Abstract

A method of treating injured skeletal muscle tissue generally includes applying to injured skeletal muscle tissue a therapeutic composition that includes a purified exosome product (PEP) and a pharmaceutically acceptable carrier. In one or more embodiments, the method includes applying from 1×1011 PEP exosomes to 1×1013 PEP exosomes to the injured skeletal muscle. In one or more embodiments, the therapeutic composition further includes a supportive matrix such as a collagen scaffold, a tissue sealant, fibrin glue, or a hydrogel.

IPC Classes  ?

• A61L 27/54 - Biologically active materials, e.g. therapeutic substances
• A61K 35/19 - PlateletsMegacaryocytes
• A61L 27/24 - Collagen
• A61L 27/52 - Hydrogels or hydrocolloids
• A61P 21/00 - Drugs for disorders of the muscular or neuromuscular system

Abstract

This document provides methods and materials involved in detecting and/or treating coccidioidomycosis (e.g., valley fever). For example, methods and materials for using a rapid antibody lateral flow assay to detect anti-CTS1 antibodies are provided. Methods and materials for treating coccidioidomycosis (e.g., valley fever) in a mammal (e.g., a human) identified as having anti-CTS1 antibodies via a lateral flow assay also are provided.

IPC Classes  ?

• G01N 33/569 - ImmunoassayBiospecific binding assayMaterials therefor for microorganisms, e.g. protozoa, bacteria, viruses
• G01N 33/543 - ImmunoassayBiospecific binding assayMaterials therefor with an insoluble carrier for immobilising immunochemicals
• G01N 33/573 - ImmunoassayBiospecific binding assayMaterials therefor for enzymes or isoenzymes

Abstract

This document provides methods and materials for treating multiple system atrophy. For example, methods and materials for using autologous mesenchymal stem cells (e.g., adipose derived mesenchymal stem cells) to treat multiple system atrophy are provided.

IPC Classes  ?

• A61K 35/28 - Bone marrowHaematopoietic stem cellsMesenchymal stem cells of any origin, e.g. adipose-derived stem cells
• A61K 9/00 - Medicinal preparations characterised by special physical form
• A61K 35/12 - Materials from mammalsCompositions comprising non-specified tissues or cellsCompositions comprising non-embryonic stem cellsGenetically modified cells
• A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Abstract

Cannula devices can be used for withdrawing venous blood from a patient and returning arterial blood to the patient after extracorporeal oxygenation. For example, this document describes dual lumen cannula devices and methods for their use with systems such as extracorporeal membrane oxygenation (ECMO) systems. The technology described herein includes a cannula device, and a methodology utilizing the cannula device, to provide complete hemodynamic support incorporating both venous drainage cannula and arterial return cannula in a single cannula device.

Abstract

This document relates to methods and materials involved in treating cancer. For example, methods and materials for using (a) APCs (e.g., dendritic cells) designed to release a viral vector that can infect a T cell (e.g., an infectious retroviral vector or an infectious lentiviral vector) and drive expression of an antigen receptor (e.g., a CAR) within that T cell and (b) an antigenic composition containing one or more antigens that can be presented to T cells within the mammal by APCs of the administered population and/or by other APCs within the mammal to produce dual specific CAR+ memory T cells are provided.

IPC Classes  ?

• A61K 35/17 - LymphocytesB-cellsT-cellsNatural killer cellsInterferon-activated or cytokine-activated lymphocytes
• A61K 39/00 - Medicinal preparations containing antigens or antibodies
• C07K 14/725 - T-cell receptors
• C12N 15/86 - Viral vectors

Abstract

A composition includes a purified exosome product (PEP) and a pharmaceutically acceptable carrier that includes a supportive matrix. The supportive matrix can include a collagen scaffold, a tissue sealant, or a fibrin sealant. A method of repairing damaged tendon tissue generally includes applying a composition that includes PEP and a pharmaceutically acceptable carrier to damaged tendon tissue. In one or more embodiments, the composition applied to the damaged tendon tissue includes a supportive matrix.

IPC Classes  ?

• A61K 9/00 - Medicinal preparations characterised by special physical form
• A61K 9/19 - Particulate form, e.g. powders lyophilised

Abstract

A method of repairing a damaged bone-tendon interface in a subject generally includes contacting the damaged bone-tendon interface with an effective amount of a composition that includes purified exosome product (PEP) and a pharmaceutically acceptable carrier. In one or more embodiments, the damaged bone-tendon interface includes complete separation of tendon from bone and the method further includes surgically reattaching the tendon to the bone. In one or more embodiments, the damaged tendon-bone interface comprises partial separation of tendon from bone and the method includes implanting the PEP composition at a site effective for contacting the PEP composition with the damaged tendon-bone interface.

IPC Classes  ?

• A61K 35/12 - Materials from mammalsCompositions comprising non-specified tissues or cellsCompositions comprising non-embryonic stem cellsGenetically modified cells
• A61K 9/00 - Medicinal preparations characterised by special physical form
• A61P 19/04 - Drugs for skeletal disorders for non-specific disorders of the connective tissue

Abstract

Systems, methods, devices, and techniques for estimating a heart disease prediction of a mammal. An electrocardiogram (ECG) procedure is performed on a mammal, and a computer system obtains ECG data that describes results of the ECG over a period of time. The system provides a predictive input that is based on the ECG data to a predictive model, such as a neural network or other machine-learning model. In response, the predictive model processes the input to generate an estimated heart disease predictive characteristic of the mammal. The system outputs the estimated heart disease prediction of the mammal for presentation to a user.

IPC Classes  ?

• A61B 5/02 - Detecting, measuring or recording for evaluating the cardiovascular system, e.g. pulse, heart rate, blood pressure or blood flow
• A61B 5/316 - Modalities, i.e. specific diagnostic methods
• A61B 5/352 - Detecting R peaks, e.g. for synchronising diagnostic apparatusEstimating R-R interval
• A61B 5/366 - Detecting abnormal QRS complex, e.g. widening
• G06N 3/04 - Architecture, e.g. interconnection topology
• G06N 20/00 - Machine learning
• G16H 40/67 - ICT specially adapted for the management or administration of healthcare resources or facilitiesICT specially adapted for the management or operation of medical equipment or devices for the operation of medical equipment or devices for remote operation
• G16H 50/20 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for computer-aided diagnosis, e.g. based on medical expert systems

Abstract

This document relates to methods and materials for assessing and/or treating mammals (e.g., humans) having a cancer (e.g., a pancreatic cancer, such as pancreatic ductal adenocarcinoma (PDAC), or a breast cancer). For example, methods and materials that can be used for assessing if a cancer (e.g., a pancreatic cancer, such as PDAC, or a breast cancer) is likely to be successfully treated are provided. This document also provides methods and materials for treating a mammal (e.g., a human) having a cancer (e.g., a pancreatic cancer, such as PDAC, or a breast cancer).

IPC Classes  ?

• C12Q 1/6886 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
• A61P 35/04 - Antineoplastic agents specific for metastasis
• G01N 33/50 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing
• G01Q 60/36 - DC mode

Abstract

This document provides methods and materials for treating cancer (e.g., liver cancer such as hepatocellular carcinoma (HCC)) using one or more stearoyl CoA desaturase 1 (SCD1) polypeptide inhibitors (e.g., a selective SCD1 inhibitor (SSI)) and one or more tyrosine kinase inhibitors.

IPC Classes  ?

• A61K 31/4545 - Non-condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
• A61K 31/445 - Non-condensed piperidines, e.g. piperocaine
• A61K 31/47 - QuinolinesIsoquinolines
• A61K 31/496 - Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
• A61K 31/501 - PyridazinesHydrogenated pyridazines not condensed and containing further heterocyclic rings
• A61P 35/00 - Antineoplastic agents

Abstract

This document provides methods, devices, and systems for detecting the presence, absence, or amount of two or more analytes present within a small volume (e.g., less than 10 μL) of a sample (e.g., a blood sample) obtained from a mammal (e.g., a human such as a human neonate). For example, methods and materials for using plasma separation and multiplex analyte detection to detect two or more analytes (e.g., proteins, carbohydrates, lipids, nucleic acids, intact cells, intact viruses, intact microorganisms, and/or chemicals) within a small volume of a blood sample are provided.

IPC Classes  ?

• B01L 3/00 - Containers or dishes for laboratory use, e.g. laboratory glasswareDroppers
• G01N 33/49 - Physical analysis of biological material of liquid biological material blood
• G01N 33/66 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving blood sugars, e.g. galactose

Abstract

The present disclosure provides SCD1-targeted radiotracers useful as diagnostic tools for diseases, disorders, and conditions where overexpression of SCD1 is implicated in pathology. Pharmaceutical compositions comprising said radiotracers and methods of using the radiotracers for imaging organs and/or tissues affected with SCD1-associated disorder are also provided. Suitable examples of SCD1-associated disorders include cancer, skin disorders, metabolic disorders, inflammatory disorders, and neurodegenerative disorders.

IPC Classes  ?

• C07D 401/12 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
• A61K 51/04 - Organic compounds

Abstract

This document provides methods and materials for assessing and/or treating mammals having a paraneoplastic neurologic syndrome (PNS). For example, methods and materials for using a Sloan Kettering virus family transcriptional corepressor 2 (SKOR2) polypeptide and/or one or more fragments of a SKOR2 polypeptide to detect the presence or absence of autoantibodies present in immune-mediated PNS are provided.

Abstract

Verbal memory impairment is a common symptom of temporal lobe epilepsy (“TLE”). The ability to encode and recall verbal memories can be probed with the classic free recall task. This study had three overarching hypotheses: 1) increased seizure frequency will lead to decreased verbal memory, 2) stimulation will modulate memory performance, and 3) stimulation will modulate the underlying neural correlates of memory. The study investigated these hypotheses in patients receiving chronic DBS to bilateral ANT. Recordings were obtained from individuals with drug resistant mesial TLE implanted with an investigational MEDTRONIC SUMMIT RC+S™ sensing and stimulation device. As patient seizure diaries are notoriously inaccurate, the patient's continuous local field potential (“cLFP”) was scored for seizures using a validated seizure classifier with trained epileptologist review, resulting in a reliable seizure diary. The subjects completed free recall memory tasks in their home environment with cLFP and behavioral data streamed to a handheld device and cloud repository. Verbal memory impairment is a common symptom of temporal lobe epilepsy (“TLE”). The ability to encode and recall verbal memories can be probed with the classic free recall task. This study had three overarching hypotheses: 1) increased seizure frequency will lead to decreased verbal memory, 2) stimulation will modulate memory performance, and 3) stimulation will modulate the underlying neural correlates of memory. The study investigated these hypotheses in patients receiving chronic DBS to bilateral ANT. Recordings were obtained from individuals with drug resistant mesial TLE implanted with an investigational MEDTRONIC SUMMIT RC+S™ sensing and stimulation device. As patient seizure diaries are notoriously inaccurate, the patient's continuous local field potential (“cLFP”) was scored for seizures using a validated seizure classifier with trained epileptologist review, resulting in a reliable seizure diary. The subjects completed free recall memory tasks in their home environment with cLFP and behavioral data streamed to a handheld device and cloud repository. Through implementation of generalized linear mixed models (GLMM), the study was able to determine that ANT stimulation modulates memory performance, but changes in the seizure rate were not predictive of changes in memory performance. Analyzing the continuous local field potential recordings from these tasks, the study found that spectral power in the theta frequency band in the left ANT and hippocampus correlated with acute memory performance and chronic therapeutic stimulation frequency received. Verbal memory impairment is a common symptom of temporal lobe epilepsy (“TLE”). The ability to encode and recall verbal memories can be probed with the classic free recall task. This study had three overarching hypotheses: 1) increased seizure frequency will lead to decreased verbal memory, 2) stimulation will modulate memory performance, and 3) stimulation will modulate the underlying neural correlates of memory. The study investigated these hypotheses in patients receiving chronic DBS to bilateral ANT. Recordings were obtained from individuals with drug resistant mesial TLE implanted with an investigational MEDTRONIC SUMMIT RC+S™ sensing and stimulation device. As patient seizure diaries are notoriously inaccurate, the patient's continuous local field potential (“cLFP”) was scored for seizures using a validated seizure classifier with trained epileptologist review, resulting in a reliable seizure diary. The subjects completed free recall memory tasks in their home environment with cLFP and behavioral data streamed to a handheld device and cloud repository. Through implementation of generalized linear mixed models (GLMM), the study was able to determine that ANT stimulation modulates memory performance, but changes in the seizure rate were not predictive of changes in memory performance. Analyzing the continuous local field potential recordings from these tasks, the study found that spectral power in the theta frequency band in the left ANT and hippocampus correlated with acute memory performance and chronic therapeutic stimulation frequency received. Not all patients are candidates for devices with chronic sensing capabilities, and this study indicates that changes in verbal memory performance can provide a suitable metric of therapy effectiveness in lieu of a reliable, objective seizure diary. But for those who do receive these and similar devices, thalamic-hippocampal spectral activities can be used to track and predict memory performance acutely and chronically, as well as predict the effect of therapeutic deep brain stimulation. Our study demonstrates chronic improvement of verbal memory with a new biomarker-based technology for remote task administration and modulation of the associated neural activities.

IPC Classes  ?

• A61N 1/36 - Applying electric currents by contact electrodes alternating or intermittent currents for stimulation, e.g. heart pace-makers
• A61N 1/05 - Electrodes for implantation or insertion into the body, e.g. heart electrode
• A61N 1/372 - Arrangements in connection with the implantation of stimulators
• G16H 20/40 - ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance relating to mechanical, radiation or invasive therapies, e.g. surgery, laser therapy, dialysis or acupuncture
• G16H 50/30 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for calculating health indicesICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for individual health risk assessment

Abstract

Methods for modulating the release and content of extracellular vesicles from target cells using electrical stimulation are provided. Compositions comprising extracellular vesicles or extracts of extracellular vesicles and methods of administering the compositions to a subject are also provided.

IPC Classes  ?

• A61N 1/36 - Applying electric currents by contact electrodes alternating or intermittent currents for stimulation, e.g. heart pace-makers
• A61K 9/00 - Medicinal preparations characterised by special physical form
• A61K 31/7105 - Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
• A61K 31/713 - Double-stranded nucleic acids or oligonucleotides
• A61N 2/00 - Magnetotherapy

Abstract

This document relates to methods and materials for detecting premalignant and malignant neoplasms. For example, methods and materials for determining whether or not a stool sample from a mammal contains nucleic acid markers or polypeptide markers of a neoplasm are provided.

IPC Classes  ?

• C12Q 1/6886 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
• C12Q 1/37 - Measuring or testing processes involving enzymes, nucleic acids or microorganismsCompositions thereforProcesses of preparing such compositions involving hydrolase involving peptidase or proteinase
• C12Q 1/40 - Measuring or testing processes involving enzymes, nucleic acids or microorganismsCompositions thereforProcesses of preparing such compositions involving hydrolase involving amylase
• G01N 33/574 - ImmunoassayBiospecific binding assayMaterials therefor for cancer

Abstract

Systems and methods can be used endoscopically to treat tumors in mediastinal, abdominal, and peri-rectal spaces. For example, this document describes systems and methods for endoscopic delivery of non-thermal pulsed electrical field or electroporation to such tumors. In addition, the systems and methods prime the immune system by re-introducing obtained and processed tissue or aspirates back to the local tumor environment after ex-vivo denaturing and emulsification of the tumor tissue or other immune enhancing substances such a monoclonal or multifunctional antibodies. The re-introduction of the processed tumor cells or immune enhancing substances will create an antigenic primed environment to the enhanced immune response generated by the pulsed electrical field. This will harness the power of the immune system as an ablative modality to the local tumor while systemically targeting metastatic disease.

IPC Classes  ?

• A61B 18/00 - Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body
• A61B 10/04 - Endoscopic instruments, e.g. catheter-type instruments
• A61B 34/10 - Computer-aided planning, simulation or modelling of surgical operations

Abstract

This document relates to methods and materials for assessing and/or treating mammals (e.g., humans) having multiple myeloma (MM). For example, methods and materials that can be used to determine whether or not a mammal (e.g., a human) having MM is likely to develop one or more therapy-related myeloid neoplasms (t-MNs) are provided. This document also relates to methods and materials for treating a mammal (e.g., a human) having MM where the treatment is selected based, at least in part, on whether or not the mammal is likely to develop one or more t-MNs.

IPC Classes  ?

• C12Q 1/6886 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
• A61K 31/198 - Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
• A61K 31/255 - Esters, e.g. nitroglycerine, selenocyanates of sulfoxy acids or sulfur analogues thereof
• A61K 31/4045 - Indole-alkylaminesAmides thereof, e.g. serotonin, melatonin
• A61K 31/4184 - 1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
• A61K 31/454 - Non-condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
• A61K 31/475 - QuinolinesIsoquinolines having an indole ring, e.g. yohimbine, reserpine, strychnine, vinblastine
• A61K 31/497 - Non-condensed pyrazines containing further heterocyclic rings
• A61K 31/635 - Compounds containing para-N-benzene- sulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonohydrazide having a heterocyclic ring, e.g. sulfadiazine
• A61K 31/675 - Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
• A61K 31/69 - Boron compounds
• A61K 31/704 - Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin, digitoxin
• A61K 31/7048 - Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin
• A61K 33/243 - PlatinumCompounds thereof
• A61K 38/07 - Tetrapeptides
• A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
• A61N 5/10 - X-ray therapyGamma-ray therapyParticle-irradiation therapy
• A61P 35/00 - Antineoplastic agents
• C12Q 1/6874 - Methods for sequencing involving nucleic acid arrays, e.g. sequencing by hybridisation [SBH]

Abstract

The present disclosure relates to a protective garment. The garment includes a body shaped for wear on a body part and a pocket assembly coupled to the body. The pocket assembly includes a first pocket comprising a wall and a pouch at least partially defined by the wall, a second pocket adjacent to the first pocket, the second pocket defining a second pouch separate from the first pouch, and an opening extending through the wall of the first pocket.

IPC Classes  ?

• A41D 13/12 - Surgeons' or patients' gowns or dresses
• A41D 13/00 - Professional, industrial or sporting protective garments, e.g. surgeons' gowns or garments protecting against blows or punches

Abstract

This document relates to methods and materials for using and/or assessing one or more senotherapeutic agents. For example, methods and materials for determining the efficacy of an anti-senescence treatment in a mammal (e.g., a human) as well as methods and materials for effectively treating a mammal with an anti-senescence treatment are provided.

IPC Classes  ?

• G01N 33/68 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving proteins, peptides or amino acids
• A61P 43/00 - Drugs for specific purposes, not provided for in groups
• C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
• A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca

Abstract

This document relates to methods for detecting and quantifying heavy and light chains of immunoglobulin using mass spectrometry techniques.

IPC Classes  ?

• G01N 33/68 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving proteins, peptides or amino acids
• G01N 30/72 - Mass spectrometers

Abstract

Systems and methods are provided to adaptively suppress reverberation clutter signals in ultrasound imaging. A robust principal component analysis (RPCA) may be used to separate a static or low dimension background signal from sparse, moving or high dimension objects in the presence of outliers. A tissue signal may be transformed to the wavelet domain to fulfill the sparsity conditions of RPCA. The use of the RPCA combined with wavelet kernels may be used to suppress reverberation clutter signals to achieve robust ultrasound attenuation coefficient estimation.

IPC Classes  ?

• A61B 8/08 - Clinical applications
• A61B 8/00 - Diagnosis using ultrasonic, sonic or infrasonic waves
• G06T 5/50 - Image enhancement or restoration using two or more images, e.g. averaging or subtraction
• G06T 7/00 - Image analysis

Abstract

This document provides methods and materials involved in identifying mammals as having, or being likely to have, a traumatic brain injury (TBI). This document also provides methods for treating mammals identified as having, or being likely to have, a TBI, based on the identification methods described herein.

IPC Classes  ?

• C12Q 1/6883 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material

Abstract

This document relates to methods and materials for assessing and/or treating mammals (e.g., humans) having brain cancer (e.g., glioblastoma (GBM)). For example, the presence of a population of CD9+extracellular vesicles (EVs; e.g., CD9+ plasma EVs) having a distinct profile in a sample (e.g., a blood sample) obtained from a mammal (e.g., a human) can be used to identify that mammal as having brain cancer (e.g., GBM). Also provided are materials and methods for treating mammals (e.g., a human) having brain cancer (e.g., GBM)

IPC Classes  ?

• G01N 33/574 - ImmunoassayBiospecific binding assayMaterials therefor for cancer
• A61K 31/495 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two nitrogen atoms as the only ring hetero atoms, e.g. piperazine
• A61K 51/00 - Preparations containing radioactive substances for use in therapy or testing in vivo
• A61P 35/04 - Antineoplastic agents specific for metastasis
• G01N 15/14 - Optical investigation techniques, e.g. flow cytometry
• A61N 5/00 - Radiation therapy

Abstract

Methods and materials for identifying and treating senescence and senescence-related and/or age-related diseases are provided herein. For example, this document provides methods and materials for using secreted PD-L2 to identify senescence/age-related diseases, as well as methods for using secreted PD-L2 as a therapeutic target for senescence/age-related diseases.

IPC Classes  ?

• G01N 33/53 - ImmunoassayBiospecific binding assayMaterials therefor
• A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
• A61P 35/00 - Antineoplastic agents
• C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
• A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Abstract

A composition for delivering a biologic to a subject generally includes a particulate substrate and an mRNA encapsulated by the particulate substrate. In some cases, the mRNA bay be indirectly attached to the particulate substrate. The mRNA encodes at least one therapeutic polypeptide. The composition may be delivered to a tissue of a subject to provide a therapeutic benefit to the tissue.

IPC Classes  ?

• A61K 31/7105 - Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
• A61K 9/00 - Medicinal preparations characterised by special physical form
• A61K 9/06 - OintmentsBases therefor
• A61K 9/127 - Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
• A61K 9/48 - Preparations in capsules, e.g. of gelatin, of chocolate
• A61K 9/51 - Nanocapsules
• A61K 47/36 - PolysaccharidesDerivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
• A61K 48/00 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseasesGene therapy
• C07H 21/04 - Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with deoxyribosyl as saccharide radical
• C12N 15/113 - Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides

Abstract

This document describes systems and methods for managing glycemia in patients with diabetes mellitus by optimizing insulin delivery dosages and timing. For example, this document describes systems and methods that utilize a patient's gastric emptying rate and other parameters to determine the optimal insulin delivery dosages and timing for the patient.

IPC Classes  ?

• A61B 5/00 - Measuring for diagnostic purposes Identification of persons
• A61B 5/083 - Measuring rate of metabolism by using breath test, e.g. measuring rate of oxygen consumption

Abstract

Subarachnoid hemorrhage (SAH) is detected using a suitably trained machine learning model. The machine learning model may take medical images as an input. Additionally or alternatively, the machine learning model may take quantified SAH blood volume (qvSAH) data and patient health data as an input. In some examples, the machine learning model may generate classified feature data indicating a risk stratification, severity of illness, and/or prognosis. A report may be generated, which may include suggestions for clinical decision support, interventions based on the severity of illness, or triaging for the patient.

IPC Classes  ?

• G16H 30/20 - ICT specially adapted for the handling or processing of medical images for handling medical images, e.g. DICOM, HL7 or PACS
• A61B 5/145 - Measuring characteristics of blood in vivo, e.g. gas concentration or pH-value
• A61B 5/00 - Measuring for diagnostic purposes Identification of persons
• G06N 20/20 - Ensemble learning
• G16H 50/20 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for computer-aided diagnosis, e.g. based on medical expert systems

Abstract

An apparatus and computerized method of classifying a patient that has been previously diagnosed to have autosomal dominant polycystic kidney disease (ADPKD) includes providing a computing device having an input/output interface, one or more processors and a memory; receiving a total kidney volume (TKV), a patient height, and a patient age for the patient via the input/output interface; determining a height adjusted TKV (HtTKV) based on the total kidney volume and the patient height using the one or more processors; determining an ADPKD classification for the patient based on the height adjusted TKV and the patient age using the one or more processors; and providing the ADPKD classification for the patient via the input/output interface.

IPC Classes  ?

• A61B 5/107 - Measuring physical dimensions, e.g. size of the entire body or parts thereof
• A61B 5/00 - Measuring for diagnostic purposes Identification of persons
• A61B 5/055 - Detecting, measuring or recording for diagnosis by means of electric currents or magnetic fieldsMeasuring using microwaves or radio waves involving electronic [EMR] or nuclear [NMR] magnetic resonance, e.g. magnetic resonance imaging
• A61B 6/03 - Computed tomography [CT]
• G06T 7/62 - Analysis of geometric attributes of area, perimeter, diameter or volume
• G16H 10/20 - ICT specially adapted for the handling or processing of patient-related medical or healthcare data for electronic clinical trials or questionnaires
• G16H 10/40 - ICT specially adapted for the handling or processing of patient-related medical or healthcare data for data related to laboratory analysis, e.g. patient specimen analysis
• G16H 30/20 - ICT specially adapted for the handling or processing of medical images for handling medical images, e.g. DICOM, HL7 or PACS
• G16H 30/40 - ICT specially adapted for the handling or processing of medical images for processing medical images, e.g. editing
• G16H 40/20 - ICT specially adapted for the management or administration of healthcare resources or facilitiesICT specially adapted for the management or operation of medical equipment or devices for the management or administration of healthcare resources or facilities, e.g. managing hospital staff or surgery rooms
• G16H 40/67 - ICT specially adapted for the management or administration of healthcare resources or facilitiesICT specially adapted for the management or operation of medical equipment or devices for the operation of medical equipment or devices for remote operation
• G16H 50/20 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for computer-aided diagnosis, e.g. based on medical expert systems
• G16H 50/30 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for calculating health indicesICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for individual health risk assessment
• G16H 50/50 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for simulation or modelling of medical disorders

Abstract

Systems and methods are provided for synthesizing information from multiple image series of different kernels into a single image series, and also for converting a single baseline image series of a kernel reconstructed by a CT scanner to image series of various other kernels, using deep-learning based methods. For multi-kernel synthesis, a single set of images with desired high spatial resolution and low image noise can be synthesized from multiple image series of different kernels. The synthesized kernel is sufficient for a wide variety of clinical tasks, even in circumstances that would otherwise require many separate image sets. Kernel conversion may be configured to generate images with arbitrary reconstruction kernels from a single baseline kernel. This would reduce the burden on the CT scanner and the archival system, and greatly simplify the clinical workflow.

IPC Classes  ?

• G06T 11/00 - 2D [Two Dimensional] image generation
• A61B 6/00 - Apparatus or devices for radiation diagnosisApparatus or devices for radiation diagnosis combined with radiation therapy equipment
• G06F 18/21 - Design or setup of recognition systems or techniquesExtraction of features in feature spaceBlind source separation
• G06F 18/214 - Generating training patternsBootstrap methods, e.g. bagging or boosting
• G06N 3/08 - Learning methods
• G16H 30/20 - ICT specially adapted for the handling or processing of medical images for handling medical images, e.g. DICOM, HL7 or PACS
• G16H 30/40 - ICT specially adapted for the handling or processing of medical images for processing medical images, e.g. editing
• G16H 50/20 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for computer-aided diagnosis, e.g. based on medical expert systems

Abstract

In an example method for increasing synaptic gain in a region of a brain of a subject, a first electromagnetic pulse is applied to a first neural element of a first neuron of the subject using a first electrode. The first neural element includes a first synapse coupled to a second neuron of the subject. Subsequent to applying the first electromagnetic pulse to the first neural element, a second electromagnetic pulse is applied to a second neural element of the second neuron using a second electrode.

IPC Classes  ?

• A61N 1/36 - Applying electric currents by contact electrodes alternating or intermittent currents for stimulation, e.g. heart pace-makers
• A61N 1/05 - Electrodes for implantation or insertion into the body, e.g. heart electrode

Abstract

Methods that implement image-guided tissue analysis, MRI-based computational modeling, and imaging informatics to analyze the diversity and dynamics of molecularly-distinct subpopulations and the evolving competitive landscapes in human glioblastoma multiforme (“GBM”) are provided. Machine learning models are constructed based on multiparametric MRI data and molecular data (e.g., CNV, exome, gene expression). Models can also be built based on specific biological factors, such as sex and age. Inputting MRI data into the trained predictive models generates maps that depict spatial patterns of molecular markers, which can be used to quantify and co-localize regions molecularly distinct subpopulations in tumors and other regions, such as the non-enhancing parenchyma, or brain around tumor (“BAT”) regions.

IPC Classes  ?

• G06V 10/776 - ValidationPerformance evaluation
• G06T 7/00 - Image analysis
• G06T 7/11 - Region-based segmentation

Abstract

in vivoin vivoin vivo and subsequently engineering at least some of the activated naïve T cells to express a CAR are provided.

IPC Classes  ?

• C12N 15/86 - Viral vectors
• C12N 5/0783 - T cellsNK cellsProgenitors of T or NK cells
• A61K 39/44 - Antibodies bound to carriers
• A61K 48/00 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseasesGene therapy
• A61P 35/00 - Antineoplastic agents
• A61P 37/04 - Immunostimulants
• C07K 14/705 - ReceptorsCell surface antigensCell surface determinants
• C07K 14/74 - Major histocompatibility complex [MHC]
• C12N 5/10 - Cells modified by introduction of foreign genetic material, e.g. virus-transformed cells

Abstract

This document provides methods and materials involved in promoting immune surveillance against cancer cells. For example, methods and materials administering one or more chemokine (C-X-C motif) ligand 14 (CXCL 14) polypeptides (and/or nucleic acids designed to encode a CXCL 14 polypeptide) to cancer cells within a mammal (e.g., a human) having cancer to promote immune surveillance against the cancer cells are provided.

IPC Classes  ?

• A61K 38/19 - CytokinesLymphokinesInterferons
• A61K 38/20 - Interleukins
• A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum

Abstract

Various embodiments of a computer-implemented executive function rehabilitation application are disclosed.

IPC Classes  ?

• A61B 5/00 - Measuring for diagnostic purposes Identification of persons
• G16H 10/20 - ICT specially adapted for the handling or processing of patient-related medical or healthcare data for electronic clinical trials or questionnaires
• G16H 10/60 - ICT specially adapted for the handling or processing of patient-related medical or healthcare data for patient-specific data, e.g. for electronic patient records
• G16H 20/00 - ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance
• G16H 40/20 - ICT specially adapted for the management or administration of healthcare resources or facilitiesICT specially adapted for the management or operation of medical equipment or devices for the management or administration of healthcare resources or facilities, e.g. managing hospital staff or surgery rooms

Abstract

This document provides methods and materials involved in treating cancer. For example, methods and materials for using chimeric antigen receptor T cells having reduced expression levels of a tumor necrosis factor receptor 2 (TNFR2) polypeptide in an adoptive cell therapy (e.g., a chimeric antigen receptor (CAR) T cell therapy) to treat a mammal (e.g., a human) having cancer are provided.

IPC Classes  ?

• C12N 15/11 - DNA or RNA fragmentsModified forms thereof
• A61K 39/00 - Medicinal preparations containing antigens or antibodies
• A61P 35/00 - Antineoplastic agents
• C12N 9/22 - Ribonucleases

Abstract

This document relates to methods and materials related to isolated polypeptides, polypeptide preparations, and methods for using one or more isolated polypeptides to activate T cells. For example, polypeptides that can be used to activate T cells to generate antigen-specific T cells are provided. In some cases, T cells activated as described herein can be administered to a mammal having cancer (e.g., MM) or a precancerous condition (e.g., MGUS) to treat the mammal (e.g., to induce an immune response against the cancer or the precancerous condition).

IPC Classes  ?

• A61K 35/17 - LymphocytesB-cellsT-cellsNatural killer cellsInterferon-activated or cytokine-activated lymphocytes
• A61K 39/00 - Medicinal preparations containing antigens or antibodies
• C07K 14/00 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof
• C12N 5/0783 - T cellsNK cellsProgenitors of T or NK cells

Abstract

In some aspects, values of features obtained from training first and second machine-learning models are analyzed to correlate at least a subset of features from the first machine-learning model with at least a subset of features from the second machine-learning model. The correlated features are then applied to update the first or second machine-learning model, or to train a third machine-learning model. In other aspects, a generator machine-learning model processes a seed and a target characteristic indicator to generate a synthetic ECG signal. The synthetic ECG signal is biased according to a target physiological characteristic represented by the target characteristic indicator. The generator machine-learning model can be trained using an expert machine-learning model and in an adversarial process with a discriminator machine-learning model.

IPC Classes  ?

• G06N 3/08 - Learning methods
• A61B 5/319 - Circuits for simulating ECG signals
• A61B 5/35 - Detecting specific parameters of the electrocardiograph cycle by template matching

Abstract

Apparatuses and methods are provided to predict or diagnose an ischemic event, such as a stroke or a transient ischemic attack (TIA). A machine-learning model such as a neural network is generated that allows for recognition of an ECG consistent with an ischemic event. A system is trained and used to process a recording of ECG data from a patient to generate a prediction indicating a likelihood that the patient will experience a stroke. In other examples, a system is trained and used to process a recording of ECG data from a patient and detect an ischemic event for the patient who did not appear to have such an ischemic event.

IPC Classes  ?

• A61B 5/00 - Measuring for diagnostic purposes Identification of persons
• A61B 5/024 - Measuring pulse rate or heart rate
• A61B 5/346 - Analysis of electrocardiograms
• A61B 5/35 - Detecting specific parameters of the electrocardiograph cycle by template matching
• A61B 5/366 - Detecting abnormal QRS complex, e.g. widening
• G06N 3/08 - Learning methods
• G16H 50/20 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for computer-aided diagnosis, e.g. based on medical expert systems
• G16H 50/30 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for calculating health indicesICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for individual health risk assessment

Abstract

e.g.e.g., a human) having cancer (e.g., cancers that exhibit little or no response to treatment with an oncolytic virus (or nucleic acid coding for an oncolytic virus) alone) are provided.

IPC Classes  ?

• A61K 35/768 - Oncolytic viruses not provided for in groups
• A61K 31/7105 - Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
• A61K 39/125 - Picornaviridae, e.g. calicivirus
• A61P 35/00 - Antineoplastic agents
• C07K 14/085 - Picornaviridae, e.g. coxsackie virus, echovirus, enterovirus
• C12N 7/01 - Viruses, e.g. bacteriophages, modified by introduction of foreign genetic material
• C12N 15/41 - Picornaviridae, e.g. rhinovirus, coxsackie viruses, echoviruses, enteroviruses
• C12N 15/86 - Viral vectors